Nova Patents
PL3461847T3

Humanized antibodies to liv-1 and use of same to treat cancer

Abstract

This record has no abstract on file.

Term

5.2 yearsto projected expiry

Projected expiry 6 December 2031, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

98 members in 27 offices

This recordMember, by publication datePriority claim17 more offices are in the list below

Priority claims20

Priority claims
DocumentOfficeKindDate
42029110United States of AmericaP
42029110United States of AmericaP
201161446990United States of AmericaP
201161446990United States of AmericaP
11847198European Patent Office (EPO)A
11847198European Patent Office (EPO)A
16200557European Patent Office (EPO)A
16200557European Patent Office (EPO)A
18204152European Patent Office (EPO)A
2011063612United States of AmericaW
2011063612United States of AmericaW
182041525–––
201161446990P–––
42029110P–––
EP20110847198–––
EP20160200557–––
EP20180204152–––
US20100420291P–––
US201161446990P–––
WO2011US63612–––

Members98

Family members, oldest first
DocumentOfficeKind
CA2819038A1CanadaA1
CA3211246A1CanadaA1
WO2012078688A2World Intellectual Property Organization (WIPO)A2
WO2012078688A3World Intellectual Property Organization (WIPO)A3
TW201241181ATaiwan Province of ChinaA
AU2011338480A1AustraliaA1
SG190938A1SingaporeA1
MX2013006365AMexicoA
US2013259860A1United States of AmericaA1
EP2648752A2European Patent Office (EPO)A2
KR20130135884ARepublic of KoreaA
CN103533957AChinaA
JP2014506120AJapanA
ZA201303803BSouth AfricaB
RU2013130609ARussian FederationA
EP2648752A4European Patent Office (EPO)A4
NZ611468ANew ZealandA
US9228026B2United States of AmericaB2
SG10201510041QASingaporeA
CN103533957BChinaB
US2016185858A1United States of AmericaA1
BR112013013781A2BrazilA2
RU2608646C2Russian FederationC2
EP2648752B1European Patent Office (EPO)B1
AU2011338480B2AustraliaB2
AU2011338480A8AustraliaA8
AU2011338480B8AustraliaB8
DK2648752T3DenmarkT3
PT2648752TPortugalT
JP6105481B2JapanB2
LT2648752TLithuaniaT
EP3156420A1European Patent Office (EPO)A1
HRP20170567T1CroatiaT1
AU2017203851A1AustraliaA1
ES2620264T3SpainT3
SI2648752T1SloveniaT1
TWI591176BTaiwan Province of ChinaB
HUE031726T2HungaryT2
PL2648752T3PolandT3
JP2017149717AJapanA
RS55843B1SerbiaB1
MX351027BMexicoB
US9783608B2United States of AmericaB2
CY1118874T1CyprusT1
US2018079810A1United States of AmericaA1
IL226754AIsraelA
IL226754BIsraelB
IL261900AIsraelA
IL261900D0IsraelD0
JP6453924B2JapanB2
AU2017203851B2AustraliaB2
EP3156420B1European Patent Office (EPO)B1
EP3461847A1European Patent Office (EPO)A1
DK3156420T3DenmarkT3
AU2019202530A1AustraliaA1
JP2019073515AJapanA
TR201905240T4TürkiyeT4
PT3156420TPortugalT
SI3156420T1SloveniaT1
KR101993921B1Republic of KoreaB1
KR20190076068ARepublic of KoreaA
ES2719548T3SpainT3
HUE043355T2HungaryT2
PL3156420T3PolandT3
SG10201912646UASingaporeA
US2020165335A1United States of AmericaA1
CY1121546T1CyprusT1
IL273607AIsraelA
IL273607D0IsraelD0
EP3461847B1European Patent Office (EPO)B1
MX2020010639AMexicoA
DK3461847T3DenmarkT3
PT3461847TPortugalT
KR20200145867ARepublic of KoreaA
KR102198189B1Republic of KoreaB1
EP3786185A1European Patent Office (EPO)A1
SI3461847T1SloveniaT1
AU2019202530B2AustraliaB2
EP3461847A8European Patent Office (EPO)A8
JP6869218B2JapanB2
HUE052806T2HungaryT2
PL3461847T3This recordPolandT3
ES2842895T3SpainT3
AU2021204473A1AustraliaA1
JP2021106599AJapanA
KR20220011811ARepublic of KoreaA
USRE48959EUnited States of AmericaE
CY1123883T1CyprusT1
BR122021020513B1BrazilB1
JP7166384B2JapanB2
JP2023011709AJapanA
IL299837AIsraelA
KR20230057485ARepublic of KoreaA
IL273607B2IsraelB2
CA2819038CCanadaC
AU2021204473B2AustraliaB2
US2024247059A1United States of AmericaA1
JP2024178209AJapanA